Open AccessSwietenia mahagony extract shows agonistic activity to PPAR γ and gives ameliorative effects on diabetic db/db mice
Author(s) -
LI Dandan,
CHEN Junhua,
CHEN Qing,
LI Guowei,
CHEN Jing,
YUE Jianmin,
CHEN Minli,
WANG Xiaoping,
SHEN Jianhua,
SHEN Xu,
JIANG Hualiang
Publication year - 2005
Publication title -
acta pharmacologica sinica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.514
H-Index - 90
eISSN - 1745-7254
pISSN - 1671-4083
DOI - 10.1111/j.1745-7254.2005.00527.x
Subject(s) - rosiglitazone , agonistic behaviour , endocrinology , medicine , peroxisome proliferator activated receptor gamma , peroxisome proliferator activated receptor , diabetes mellitus , chemistry , receptor , psychiatry , aggression
Aim: To search the peroxisome proliferator‐activated receptor γ (PPARγ) agonists from Swietenia mahagony extract ( Sm E) and observe the possible ameliorative effects of Sm E on diabetic db/db mice. Methods: The PPARγ agonistic activity of Sm E was screened by yeast‐two hybrid system. The blood glucose levels of diabetic db/db mice were measured using a blood glucose level monitor and the data were statistically analyzed by NDST8.8W software. Results: By using the clinical drug rosiglitazone as a positive control, it was found that the PPARγ agonistic activity of Sm E at a concentration of 50 μg/L was approximately half that of 35.7 μg/L (0.1 μmol/L) of rosiglitazone. At the dose of 1000 mg/kg, Sm E remarkably decreased the blood glucose concentration of db/db mice from (15.26±2.98) to (7.58±2.20) mmol/L, and reduced the blood glucose levels by 55.49% compared with the control group ( P <0.01). Conclusion:Sm E shows agonistic activity to PPARγ and can ameliorate the blood glucose levels of diabetic db/db mice. Sm E may be thus used as a potential agent for diabetes therapy.